It has been shown that in breast cancer with a poor prognosis, TSPYL5 promotes the degradation of the tumor suppressor p53 by directly inhibiting ubiquitin-specific peptidase 7 (USP7)—the p53 deubiquitinase [9]. Here, USP7 is linked to breast carcinoma.